低温灌注下肝切除术:单中心110例分析
该单中心回顾性分析纳入1997至2024年110例低温灌注下肝切除术(LR-HypoT),其中恶性100例、良性10例。90天死亡率为15.5%,术后肝衰竭(POLF)发生率为29%且是主要死因,胆道重建和扩大肝切除是POLF风险因素。癌症患者中92%不符合肝移植标准,但长期结果在约三分之一患者中令人鼓舞。
要点
- LR-HypoT多数可原位实施,90天死亡率为15.5%。
- POLF发生率29%,是90天死亡主因,胆道重建和扩大肝切除增加其风险。
- 癌症患者结局无效率为30%,但约三分之一可获得鼓励性长期生存。
核心结论
- LR-HypoT多数可原位完成,在不可切除或不可移植的恶性肿瘤患者中约三分之一可获得鼓励性长期结果。
研究设计与样本
- 单中心回顾性分析1997至2024年连续110例低温灌注下肝切除术,恶性100例、良性10例。
主要发现
- 90天死亡率为15.5%(17/110)。
- POLF发生率为29%(32/110),占90天死亡的82.3%(14/17)。
- 胆道重建(P=0.023)和需扩大肝切除(P=0.033)是POLF的风险因素。
- 癌症患者早期肿瘤复发率为17.2%,结局无效率为30.0%。
- 中位随访100(3-183)个月,5年生存率总体为36.8%,恶性患者为30.0%,良性患者为100%。
临床怎么用
- LR-HypoT可考虑用于部分不可切除或不可移植的恶性肿瘤患者,但需警惕POLF风险。
- 胆道重建和扩大肝切除患者应加强术后肝功能监测。
局限性
- 单中心回顾性设计可能限制结论的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To propose a surgical strategy guiding the total vascular exclusion (TVE) subtype during liver resection under hypothermic perfusion (LR-HypoT); to analyze the latter's outcome futility, the risk of severe postoperative liver failure (POLF); and whether LT could have been an alternative treatment. BACKGROUND: Series on LR-HypoT lack granularity, and none analyzed outcome futility or liver transplantation (LT) as an alternative treatment. METHODS: Single-center retrospective analysis of 110 consecutive LR-HypoT performed between 1997 and 2024 for malignant (n=100) or benign tumors (n=10). The subtypes of TVE used, 90-D mortality, and outcome futility (90-D death or tumor recurrence within six months of surgery) were analyzed. Risk of POLF was analyzed by recursive partitioning analysis. RESULTS: LR-HypoT was performed in situ in 108 (98.2%) patients and ex situ in 2 (1.8%). 90-D mortality was 15.5% (n=17). POLF, the leading cause of 90-D mortality (14/17, 82.3%), occurred in 32 (29%) patients. Biliary reconstruction (P=0.023) and the need for extended hepatectomy (P=0.033) were the two risk factors for POLF. In patients with cancer, early tumor recurrence and outcome futility rate was 17.2% and 30.0%, respectively. With a median follow-up of 100 (3-183) months, 5-years survival was 36.8%, 30.0%, and 100% for the study population, patients with malignant or benign tumors, respectively. LT criteria were not met by 92% (92/100) of patients with cancer. CONCLUSIONS: LR-HypoT can be performed in situ in most cases. In patients presenting otherwise unresectable or untransplantable malignant tumors, encouraging long-term results can be obtained in one third of patients.
引用
- Azoulay D, Ammar-Khodja N, Allard MA, et al. Hepatectomies under Hypothermic Perfusion of the Liver: Analysis of 110 Cases from a Single Center. Ann Surg. 2025. PMID: 41225706. doi:10.1097/SLA.0000000000006982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。